COVID-19 Pandemic and Posttraumatic Growth in Residents of a Continuing Care Retirement Community: A Mixed Methods Study.

COVID has impacted life for the older adult population living in residential settings affecting psycho-social well-being. Risk for COVID is associated with increasing age and pre-existing health conditions. The purpose of the study was to investigate the post-traumatic growth (PTG) experience among older adults, and the impact of COVID and associated regulatory precautions, on well-being for older adults living in a continue care community (CCC). A parallel mixed-methods approach was used to explore the experience of older adults with PTG. Quantitative data were analyzed using descriptive statistics. Qualitative data were analyzed using content analysis to identify emergent themes most frequently reported from open-ended responses. Older adults (N=98) living in a single CCC completed the survey. Age ranged from 67-99 years (mean = 86) with over 90% identifying as non-Hispanic White; and female (75%). Over half (51%) reported social-psychological issues, including anxiety (32%) and depression (31%); 41% reported knowing residents who died during COVID, attributed to will to live (35%), social isolation (30%) and coexisting health conditions (75%). Qualitative analysis revealed 13 subthemes related to 5 major PTG concepts: New possibilities, relating to others, personal strength, spiritual growth and appreciation for life. This study provides a deeper understanding of how older adults residing in a CCC coped with COVID and their experiences. Results indicated that older adults experienced positive changes and PTG despite challenges. Healthcare providers should recognize these potential positive changes and growth and use them as a source for improving older adult well-being when facing pandemic challenges.

Metabolic biomarkers measured from single blood test can identify apparently healthy people at high susceptibility for developing severe pneumonia, and may also be useful for preventive COVID-19 screening.

Reply

COVID-19 and Kidney Disease Disparities in the United States

Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma

Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19

Peer Reviewed

Management of lung transplantation in the COVID-19 era-An international survey.

Potential conflict of interest: Nothing to report. On December 29, 2019, health authorities in China reported 27 cases of an unusual pneumonia, respiratory failure, and death linked to attendance at a live animal market in Wuhan.1,2 On January 7, 2020, Chinese scientists confirmed a novel coronavirus, 2019‐nCoV, as the causative agent.3 Studies revealed >80% genetic homology of 2019‐nCoV with coronaviruses of bats, presumably the original host; pangolins, suggesting this animal sold at the market as an intermediate host; and another human coronavirus, SARS‐CoV, the cause of severe acute respiratory syndrome (SARS).3,4 All evidence indicates that SARS‐CoV‐2 is of animal and not laboratory origin.5 The World Health Organization (WHO) later named the novel virus SARS‐CoV‐2 and the related disease coronavirus disease 2019 (COVID‐19).2,3 SARS‐CoV‐2 spread quickly through communities in China and other countries (Fig. 1). On January 20, 2020, the first case was recognized in the United State when a 35‐year‐old man presented to an urgent care clinic in Snohomish, Washington.6,7 On January 30, 2020, WHO declared the outbreak a Public Health Emergency of International Concern. On March 11, 2020, WHO designated COVID‐19 a pandemic. Almost all countries are implementing public health measures to prevent SARS‐CoV‐2 transmission and are marshaling clinical care for patients with COVID‐19. This review highlights key features of SARS‐CoV‐2 infection, the epidemiology and clinical course of COVID‐19, and interventions to stop the growing COVID‐19 pandemic.Fig 1: Chronology of the COVID‐19 pandemic.Epidemiology By March 11, 2020, 105 countries had reported 118,319 confirmed COVID‐19 cases and 4292 deaths.2 Outside China, large epidemics emerged in South Korea, Iran, and Italy. By March 14, 2020, approximately one in four COVID‐19 cases and deaths were in Europe. The US epidemic accelerated, with cases doubling every 6 to 7 days.7 By March 29, 2020, more than 100,000 persons had COVID‐19 in the United States, the largest burden of COVID‐19 globally.2,7 As of April 29, 2020, the COVID‐19 pandemic has grown to more than 3 million confirmed cases and more than 206,000 deaths in 179 countries. The United States now has more than 1 million cases (33%) and more than 50,000 deaths (25%).2,7 The potential is high for large COVID‐19 epidemics in Brazil, Russia, India, and many African countries. SARS‐CoV‐2 is transmitted directly through inhalation or mucosal surface exposure to an infected person's respiratory droplets or indirectly when touching the face after contact with contaminated objects.2,4,7 SARS‐CoV‐2 can remain viable on environmental surfaces for up to 72 hours.8 SARS‐CoV‐2 is highly infectious with an R0 of approximately 2.2 to 3.0, meaning each infected person will infect about two to three other persons.7 Large COVID‐19 outbreaks have occurred in health care facilities, households, cruise ships, religious services (e.g., funerals), and other large gatherings1,2,7 Individuals can transmit SARS‐CoV‐2 before, during, and after symptomatic disease. As many as half of individuals with SARS‐CoV‐2 infection have no symptoms.7 Clinical Presentation Similar to SARS‐CoV, SARS‐CoV‐2 binds to angiotensin‐converting enzyme 2 (ACE2) receptors for entry via endocytosis into alveolar epithelial cells, as well as other cells with ACE2 receptors in the heart, gastrointestinal tract, and kidneys.2,4 COVID‐19 results from SARS‐CoV‐2 replication, causing early cell death (i.e., apoptosis) and provoking a storm of proinflammatory cytokines (e.g., interleukin‐6 [IL‐6]) disrupting alveolar walls with resulting fluid accumulation in alveoli.4 The incubation period from infection to onset of COVID‐19 disease is typically 5 to 7 days (range 1‐14 days).1,2,7 The most common symptoms of COVID‐19 are fever and nonproductive cough (Table 1).1,4,7,9 The Centers for Disease Control and Prevention (CDC) recently added anosmia and ageusia, the loss of smell and taste, as COVID‐19 symptoms.7 Laboratory findings are remarkable for a normal leukocyte count, lymphopenia, and elevated C‐reactive protein.1,6,8 Most hospitalized patients with COVID‐19 have a bilateral ground‐glass appearance on chest computed tomography (CT) scan consistent with viral pneumonia. Table 1 - Clinical Features of COVID‐19 in Wuhan and Multiple Other Locations in China Clinical Features Wuhan, China Multiple Locations, China Number of patients 10,999 3,062 Symptoms Fever 89% 80% Cough 68% 63% Expectoration 34% 42% Dyspnea 19% 34% Fatigue/Myalgia 38% 46% Headache 14% 15% Nausea/Vomiting 5% 10% Diarrhea 4% 13% Laboratory results Leukocytes in normal range 94% 70% Lymphopenia 83% 57% Increased C‐reactive protein 61% 74% Alanine aminotransferase above upper limit of normal 21% 29% Imaging Abnormal chest CT 86% 89% Bilateral infiltrates (ground glass) 56% 76% Acute respiratory distress syndrome 6% 20% Mortality 1.4% 6% Data are from Guna et al.1 and Centers for Disease Control and Prevention.7 Today, reverse transcription polymerase chain reaction (RT‐PCR) is the COVID‐19 diagnostic test.2,7 RT‐PCR sensitivity is highest for testing bronchial alveolar lavage fluid (93%) and declines for sputum (72%) and nasal swab (63%) specimens.10 COVID‐19 diagnosis might require repeat testing.2,7 Serological tests to detect SARS‐CoV‐2 IgM and IgG antibodies are available. However, because of test sensitivity and other quality concerns, the US Food and Drug Administration (FDA; https://www.fda.gov) advises current serological tests are best used for surveillance and research, and not as the sole basis for COVID‐19 diagnosis. COVID‐19 is commonly a mild disease. Of the first 72,314 COVID‐19 disease reported in China, 81% had no or mild pneumonia, 21% had severe dyspnea and radiological evidence of pulmonary disease, and 5% progressed to SARS.1 Individuals can be ill for a week or longer before experiencing severe symptoms. The risk for severe COVID‐19 disease is highest for men, older adults, and patients with certain comorbidities. In the United States, 80% of reported COVID‐19–related deaths are among people aged ≥65 years.7,9,11 Deaths are rare among persons <24 years of age.1,7,11 In the United States, most hospitalized patients with COVID‐19 have comorbid conditions, including obesity, hypertension, diabetes, and cardiovascular disease7,11 (Table 2). Although listed by the CDC as a comorbid condition associated with severe COVID‐19, chronic liver disease, including cirrhosis, has not been a common comorbidity associated with hospitalization in the United States (Table 2). The high prevalence of comorbid conditions can explain, in part, African Americans' increased risk for hospitalization with COVID‐19 disease.5 Variable comorbidity prevalence contributes to differences in national COVID mortality. Globally, crude fatality rates for COVID‐19 range from 0.2% in Singapore, to 2.0% to 3.0% in South Korea and Germany, to 4.3% for the United States, and to 10% to 13% in Spain, Italy, and the United Kingdom.2,5 Table 2 - Comorbidities Among Persons With COVID‐19 Disease, United States Condition United States* New York City Not Hospitalized Hospitalized Intensive Care Hospitalized Patients 5143 1037 457 5700 One or more condition 27% 71% 78% 88% Obesity 42% Hypertension 57% Diabetes mellitus 6% 24% 32% 34% Cardiovascular disease 5% 23% 29% 18% Chronic renal disease 1% 9% 12% 0.6% Chronic liver disease 1% 1% 2% 9% Immunocompromised 3% 6% 9% 2% Mortality 21% Total 21% 1 Comorbidity 88% *Based on data from the CDC for all 50 states and territories. Otherwise, data are Richardson et al.11 The search for effective therapies and a vaccine is occurring at a remarkable pace, with at least 29 studies of therapeutic agents and 5 studies of candidate vaccines registered on ClinicalTrials.org (https://www.clinicaltrials.gov). On May 1, 2020, the FDA granted Emergency Use Authorization of remdesivir, a broad‐spectrum antiviral nucleotide prodrug for treatment of severe COVID‐19. Studies of monoclonal antibodies against IL‐6 and hyperimmune immunoglobulin are in progress. Following reports of serious cardiac arrythmias, the FDA cautioned clinicians of prescribing hydroxychloroquine or chloroquine for treatment of COVID‐19. A safe and effective vaccine, if successfully developed, probably will not be available for 12 to 18 months. Prevention In the absence of a vaccine, prevention is composed of a combination of nonpharmacological interventions for suppression of transmission to R0 <1 and mitigation of the number of patients with COVID‐19 who require intensive care and mechanical respiratory support.12 Interventions include improved personal hygiene promotions, symptomatic screening and laboratory testing for case detection, contact tracing, household quarantine of those with transmission risks, and social distancing (Table 3). The United States and most other countries have implemented extensive travel restrictions, workplace and school closures, and cancellation of sporting and other large public events. China, South Korea, and Taiwan successfully curbed large COVID‐19 epidemics with prompt scale‐up of testing, contact tracing, and quarantine.2,4,7 In the United States, although testing rates are low, models suggest prevention measures are reducing transmission and future deaths.13 The US government recently recommended increased COVID‐19 surveillance, testing, and contact tracing with modified social distancing measures to sustain SARS‐CoV‐2 prevention while opening up education and commerce.14 Table 3 - Prevention Measures to Reduce Risks for COVID‐19, Priority Populations for Testing, and Information Resources Prevention measures to reduce risks for COVID‐19 Practice good hygiene ○ Wash hands often for >20 seconds with soap and water or 60% alcohol sanitizer ○ Avoid touching eyes, nose, and mouth with unwashed hands ○ Sneeze or cough into a tissue or inside of the elbow ○ Disinfect surfaces and used items frequently with soap and water and Environmental Protection Agency–registered household disinfectants or bleach solution (4 teaspoons [20 mL] bleach per quart [or 1 L] water) Limit close social contact ○ Learn signs and symptoms of COVID‐19, and follow local disease trends ○ Stay home as much as possible, particularly persons who are ill, older (>65 years) adults, and those at risk for severe COVID‐19 ○ Persons who are ill, call a health care provider ○ Consider 2‐week supply of medications, food, and other essentials ○ When out in public, keep social distance of at least 6 feet and wear a cloth face cover ○ Avoid gatherings of >10 persons ○ Work or attend school from home ○ Avoid unnecessary travel ○ Avoid visits to nursing homes or long‐term retirement facilities Protect patients and health care workers ○ Reduce facility risks: screen for COVID‐19 symptoms on entry; reduce visits; practice telemedicine ○ Isolate symptomatic patients as soon as possible ○ Protect health care personnel with recommended infection‐control procedures Recommended testing in consultation with health care provider Hospitalized patients Persons with symptoms of COVID‐19 ○ Health care facility workers ○ Patients in long‐term care facilities ○ Patients >65 years of age ○ Patients with underlying conditions with symptoms ○ First responders Critical infrastructure workers and others with symptoms Health care facility workers and first responders Persons mildly ill in communities with high numbers of COVID‐19 hospitalizations Good information resources Centers for Disease Control and Prevention: https://www.cdc.gov/coronavirus/2019-ncov/index.html World Health Organization: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Infectious Disease Society of America: https://www.idsociety.org/public-health/COVID-19-Resource-Center/ American Association for the Study of Liver Diseases: https://www.aasld.org/about-aasld/covid-19-resources European Association for the Study of the Liver: https://easl.eu/covid-19-and-the-liver/ European Centre for Disease Control and Prevention: https://www.ecdc.europa.eu/en/covid-19-pandemic The Society for Healthcare Epidemiology of America: https://www.shea-online.org/ Summary SARS‐CoV‐2 is a new human pathogen, readily spread via respiratory droplets and the cause of the growing COVID‐19 pandemic. Men, older adults (>65 years old), and persons with comorbidities are at risk for severe COVID‐19 and death. Countries have successfully suppressed transmission and mitigated needs for intensive care with robust case/contact detection (testing), isolation of infected/exposed persons, and social distancing. To stop the COVID‐19 pandemic, the challenge is for all countries to scale up and sustain prevention measures while awaiting the arrival of effective vaccines and therapies.

Changes in Older People's Activities During the Coronavirus Disease 2019 Pandemic in Japan

COVID-19 and Long-term Planning for Procedure-based Specialties During Extended Mitigation and Suppression Strategies

EditorialLung health in Africa: challenges and opportunities in the context of COVID-19Obianuju B. Ozoh, Bertrand Hugo Mbatchou Ngahane, Heather J. Zar, Refiloe Masekela, Jeremiah Chakaya, Joseph Aluoch, and on behalf of the Pan African Thoracic SocietyObianuju B. OzohDepartment of Medicine, Faculty of Clinical Sciences, College of Medicine, University of Lagos, and The Lagos University Teaching Hospital, Lagos, Nigeria, Bertrand Hugo Mbatchou NgahaneDepartment of Medicine, Douala General Hospital, University of Douala, Douala, Cameroon, Heather J. ZarDepartment of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital and SA-MRC Unit for Child and Adolescent Health, University of Cape Town, Cape Town, South Africa, … See all authors Published Online:07 Sep 2021https://doi.org/10.1152/ajplung.00322.2021This is the final version - click for previous versionMoreFiguresReferencesRelatedInformationSectionsINTRODUCTIONADULT LUNG HEALTH IN AFRICA IN THE CONTEXT OF COVID-19CHILD LUNG HEALTH IN AFRICA IN THE CONTEXT OF COVID-19TUBERCULOSIS AND COVID-19 IN AFRICA: WHAT HAS HAPPENED?STRATEGIES TO MITIGATE THE COVID-19 PANDEMIC: WHERE WE ARE AND WHERE WE NEED TO BEDISCLOSURESAUTHOR CONTRIBUTIONSAUTHOR NOTES PDF (346 KB) ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookXLinkedInWeChat INTRODUCTION The emergence of coronavirus disease 2019 (COVID-19) in December 2019 caused unprecedented challenges to healthcare worldwide. Although at the beginning of the COVID-19 pandemic it was projected that Africa would suffer a huge pandemic, the reality is that the number of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infections and deaths from COVID-19 have not been as large as projected. Africa has currently reported ∼4.6 million confirmed cases of SARS-CoV-2 infection against a global total of 190.5 million confirmed infections and 107,000 deaths against the global total of 4 million deaths from COVID-19, with a contribution of 2.4% and 2.7% of all confirmed SARS-CoV-2 infections and COVID-19 deaths, respectively (1). The reasons for this may include the relatively youthful population of the region, genetic factors, climatic conditions, high exposure to other infectious diseases with the development of trained immunity, and use of COVID-19 mitigation measures very early in the evolution of the COVID-19 pandemic (2). However, lack of testing for diagnosis or poor access to healthcare facilities with many deaths outside such facilities may also influence these estimates. The COVID-19 pandemic has caused global devastation among high-income and low- and middle-income countries (LMICs). In Africa and other LMICs, the direct impact including COVID-related illness and deaths as well as the indirect effects on economies, other health-related conditions, education, and social services have been overwhelming and are likely to endure, threatening to shape the future of its population. This pandemic poses challenges to the well-being of both adults and children in Africa, which is made more profound by weak health systems, preexisting poor population health, and low socioeconomic status pervasive in the continent. Also, high exposure to potentially harmful environmental factors such as tobacco smoke or air pollution may be associated with a greater risk of severe COVID-19. Furthermore, the ability of health systems to deal with increasing numbers of people with COVID-related illness and to upscale and widely implement vaccination against SARS-CoV-2 is a challenge. However, within these challenges also lies opportunities for the continent to leverage this health crisis to improve the lives of its people. The ability to mitigate this pandemic requires a multifaceted approach embracing global partnerships and alliances.ADULT LUNG HEALTH IN AFRICA IN THE CONTEXT OF COVID-19 Chronic respiratory diseases (CRDs), including asthma and chronic obstructive pulmonary disease (COPD), are common and rising public health concerns in Africa (3, 4). These diseases were relatively neglected with no public health programs in place for them in most countries in Sub-Saharan Africa (sSA) (5). Consequently, the provision of healthcare for CRDs such as asthma and COPD has been suboptimal even before the COVID-19 pandemic. The pandemic has further compromised the situation and negatively impacted care and treatment for these diseases. Most guidelines recommend that pulmonary function tests should be limited to the most essential tests when possible for fear of transmission of SARS-CoV-2 (6). This recommendation is likely to constrain efforts that were being made to promote spirometry testing in sSA and will further compromise the diagnosis of CRDs in the continent (7). We hypothesize that in the African setting, the COVID-19 pandemic has reduced the number of people diagnosed with asthma, worsening the already existing wide gaps between prevalent cases of asthma and those accessing appropriate care and treatment for their disease for several reasons. These reasons include inadequate services for asthma as health resources are diverted to the COVID-19 response as well as fear of a diagnosis of COVID-19 and the attendant consequences, including isolation, keeping people away from healthcare facilities for fear of infection with SARS-CoV-2 infection, which is perceived by the population as fertile grounds for the transmission of this virus. Patients with asthma exacerbations who arrive at healthcare facilities may have delayed care for their disease as they are screened and tested for SARS-CoV-2 infection and may be at increased risk of acquiring infection with this virus if they are placed in holding areas where persons suspected to have COVID-19 are isolated as they await their COVID-19 test results. These interactions have not been studied in the African setting, and we urge African researchers, their partners, and funders to prioritize this area of research to gather the evidence needed to develop robust mitigation measures. It has been documented that people with chronic respiratory disease are at increased risk of developing severe disease when infected with SARS-CoV-2 (8). Data in the African setting are, however, sparse, and it remains unclear if people with asthma and COPD, especially those with COPD unrelated to tobacco smoking and people with tuberculosis (TB)-associated chronic lung disease, which are common forms of chronic respiratory disease in Africa, have an elevated risk of severe COVID-19. Similarly, there is a high burden of the human immunodeficiency virus (HIV)-associated disease, especially in sSA; HIV-infected people, especially those whose disease is not well controlled with antiretroviral therapy or those with comorbidities such as diabetes or renal impairment, may be at increased risk for developing severe COVID-19 (9). Other underlying illnesses that place people at risk for developing severe COVID-19 are common in Africa. Cardiovascular disease including hypertension is one of the commonest noncommunicable diseases in the African population (10). Diabetes and obesity are increasingly emerging as important chronic illnesses in African populations (11). Each of these places individuals at increased risk for developing severe COVID-19. Acute lower respiratory infections (ALRIs) are more common in LMICs, with ∼70% occurring in South Asia and sSA (12). Pneumonia due to COVID-19 may be difficult to distinguish from bacterial community-acquired pneumonia. The lack of diagnostic tests for SARS-CoV-2 in the early days of the pandemic might have delayed the diagnosis and optimal management of bacterial pneumonia. Avoidance of medical settings by patients might have led to the late diagnosis of pneumonia from other causes and a consequent increase in pneumonia-related mortality overall. The COVID-19 outbreak has again brought the weaknesses of health systems in Africa to the forefront. In emergency departments of many hospitals across sSA, there is a lack of equipment and commodities, such as pulse oximeters and oxygen that are critical for the identification and treatment of people with serious lung disease. This situation implies that outcomes for people presenting to these facilities with COVID-19 and other respiratory emergencies, including asthma and COPD exacerbations, are likely to be poor.CHILD LUNG HEALTH IN AFRICA IN THE CONTEXT OF COVID-19 Respiratory illnesses remain a predominant cause of morbidity and mortality in African children, from both infectious causes and chronic noncommunicable disease. As children constitute a third to half of the African population, this comprises a large burden of illness. Pneumonia and tuberculosis disease remain key challenges for child health, whereas asthma is the commonest noncommunicable disease in children and adolescents. African children have been largely spared from moderate or severe illness with SARS-CoV-2 through the COVID-19 pandemic, as has occurred globally, but the indirect effects have substantially impacted child health. The incidence and severity of childhood pneumonia have reduced substantially with socioeconomic improvement, improved immunization strategies, particularly pneumococcal conjugate vaccine (PCV) and Haemophilus influenzae type b conjugate vaccine (Hib), and better prevention and management of HIV. Nevertheless, pneumonia remains the commonest cause of death in children under 5 yr outside the neonatal period, with almost 800,000 deaths in 2018, with more than half of the deaths occurring in Africa or Southeast Asia (12, 13). Childhood TB is common in Africa and has been reported to contribute up to 20% of the overall caseloads (14), although this is probably an underestimate given the challenges in confirming TB in children and lack of notification of childhood cases. Mycobacterium tuberculosis has increasingly been recognized as a pathogen in the context of acute pneumonia in children, comprising a large proportion of cases. Factors associated with the high burden and severity of respiratory disease in African children also include high exposure to air pollution or tobacco smoke, under-resourced health systems, and lack of access to effective preventive or management strategies. Furthermore, early life respiratory infection, particularly pneumonia or TB, may lead to a long-term impairment of health, setting a trajectory for the development of CRD through the course of life (15). Asthma is the commonest chronic disease in African children, with an increasing prevalence in both urban and rural settings. Although childhood asthma was regarded as rare in Africa, global epidemiological studies have shown that the prevalence in African children is similar or higher than the global average (16). Furthermore, asthma in Africa may be frequently undiagnosed, untreated, and more severe (17). Access to routine health services and follow-up during the pandemic may have compromised care of these children further. HIV-associated chronic lung diseases or bronchiectasis or bronchiolitis obliterans following lower respiratory tract infection or TB are other causes of chronic respiratory illness in African children. Although children and adolescents constitute a very small proportion of cases of COVID-19 and of COVID-associated mortality in Africa, similar to the patterns seen globally, the indirect effects on child health have been substantial. These include disruptions in delivery of essential healthcare services such as immunization and HIV or TB programs, increasing poverty levels, disrupted schooling, lack of access to school feeding schemes, and diversion of resources away from maternal and child health to adult COVID responses. With a large informal economic sector with little social protection in Africa, levels of poverty and hunger are increasing at an alarming rate, increasing the susceptibility of children to severe pneumonia from other pathogens, which is of concern. However, the use of nonpharmacological interventions, including universal mask wearing, social distancing, and hand hygiene, has reduced the incidence of influenza or respiratory syncytial virus-related illness, with reductions in a number of cases and hospitalization of children. Nevertheless, late presentation with severe disease may occur as families may be reluctant to attend health facilities in the context of COVID-19 or these may be inaccessible. Parental or family loss due to COVID-19 has compounded the effects on child health. While immunization program against COVID-19 has been initiated in many African countries, the rollout is slow (18). Greater coverage is urgently needed to protect populations including children and adolescents, who may be indirectly protected with high coverage of adult population groups.TUBERCULOSIS AND COVID-19 IN AFRICA: WHAT HAS HAPPENED? Sub-Saharan Africa bears a disproportionate burden of tuberculosis. It is currently estimated that ∼14% of the global population of ∼7.8 billion people live in sSA; however, in 2019, this region accounted for 25% of all incident cases of TB in the world (19). The drivers of the large burden of TB in the African setting include the concurrent HIV epidemic and rampant poverty. Nearly 75% of all people living with HIV are in sSA (20), and of the 736 million people who lived on less than $1.90 in 2015, 413 million (56%) lived in sSA (21). The link between poverty and TB has been firmly established and known for nearly a century, and it is therefore not surprising that Africa, with a large proportion of people living in extreme poverty, suffers a high burden of TB. An important question that needs to be addressed is the impact that COVID-19 has had on the TB epidemic in the African setting and what may be expected to happen as the COVID-19 pandemic continues to evolve. The first major concern has been the influence of COVID-19 on TB case findings. As a result of both societal fear of a new disease that had been depicted to be highly lethal and the mitigation measures put in place to protect society and the healthcare system, TB case findings declined significantly. Tuberculosis surveillance data from high TB-endemic settings have revealed significant declines in TB notification between 2019 (the pre-COVID era) and 2020 (the COVID era) (22). The decline in TB notification in the African settings has been of the order of ∼20% (23, 24). The decline in TB notifications has been attributed to disruption in TB service provisions, some of which have been related to closure of facilities that provide TB services and redirection of resources, including human, financial, and equipment (such as the Xpert platforms and others) to the COVID-19 response to confront a public health threat that was perceived to be more urgent and bigger. In addition, travel restrictions and a fear of health facilities have contributed to alterations in health-seeking behavior of the population. The full impact of these developments is not yet known, but it has been projected that TB incidence and deaths will rise globally to set the world back by several years in the fight against this age-old disease. In Sub-Saharan Africa, it has been projected that COVID-19 will lead to economic declines, with shrinkage of the gross domestic product of African countries of up to 1.4% with smaller economies contracting by a margin of up to 7.8% that will increase poverty rates (25). The rise in poverty in Africa because of the COVID-19 pandemic implies a rise in the burden of TB. The second effect of the COVID-19 pandemic is on treatment outcomes. With disruptions in TB service provision and the hurdles occasioned by COVID-19 mitigation measures in accessing health services combined with societal fear of health services, disruptions in TB treatment were expected to become more common. We need to see if this projection will be confirmed as national TB programs carry out cohort analysis of treatment outcomes of persons diagnosed with TB in 2020 and 2021 (in the COVID-19 era) to allow for comparisons to be made with those diagnosed and placed on treatment in the pre-COVID period. Preliminary data from Kenya, Malawi, and Zambia suggest that TB treatment outcomes in the COVID-19 era were slightly better than in the pre-COVID-19 era (26). Third, there have been concerns that persons with current or previous TB may have a worse COVID-19 disease clinical course than those without these conditions. The data so far suggests that this may be so (26), which is extremely worrying for countries in Sub-Saharan Africa with a large burden of TB, highlighting the need to develop robust mechanisms to protect these individuals from acquiring SARS-CoV-2 infections and consequently developing severe disease. Prioritizing these people in vaccination programs may be very helpful. In a continent that is struggling with a myriad of health problems on the background of very weak health systems, the COVID-19 pandemic could not have come at a worse time. The effect of this pandemic on TB is expected to be enormous and will add to the woes of a continent that has already been off track with its efforts to achieve End TB Strategy targets. All is not lost, however, and with concerted efforts including advocacy efforts to ensure African governments allocate sufficient resources to build and sustain robust and resilient health systems, the expected trajectory of the TB epidemic in Africa during and after the COVID-19 pandemic can be reset to get the African continent to reach the targets of the End TB Strategy. African governments must address the social determinants of TB. Now is the time to ramp up efforts to lift people out of poverty in Africa. On the other hand, national TB programs, TB researchers in Africa, communities, and other stakeholders need to develop, test, and scale up innovations to expand TB case findings in Africa and to ensure that all people on treatment for TB are supported throughout their TB journey and beyond. Now is the time to step up the fight against this disease. Africa should not and must not be left behind in the fight against TB, COVID-19 notwithstanding.STRATEGIES TO MITIGATE THE COVID-19 PANDEMIC: WHERE WE ARE AND WHERE WE NEED TO BE Mitigation strategies for the COVID-19 pandemic aim to slow the spread of the disease and protect the population while being cognizant of the need to minimize the impact of these strategies on the well-being of the people they aim to protect. Safe hygiene practices, physical distancing, and mask wearing are fundamental to any mitigation action and have been adopted globally to curb the spread of SARS-CoV-2. Universal mask wearing has been found to be a highly effective practice that reduces transmission in both experimental models and real-life situations (27, 28). When adhered to, mask wearing also contributes to the reduced spread of other respiratory diseases including influenza virus or respiratory syncytial virus. However, adherence to mask-wearing has varied, being politicized in some parts, unenforced in others, or just simply ignored. Lockdown or mandatory stay-at-home measures as a mitigation strategy truncate the spread of the virus and protect the health system but have adverse social, economic, educational, and health consequences (29). The adverse economic impacts of COVID-19-related lockdowns have been found to be more profound in the African setting due to high rates of poverty, high reliance on daily wages, and lack of social safety nets (30). Furthermore, reports of increases in sex-based violence during lockdowns in many parts of Africa and non-COVID deaths due to limited access to healthcare services have been documented (31, 32). Therefore, lockdown as a COVID-19 mitigation strategy has not worked well in Africa and in many instances its enforcement has been met with protests and crackdowns resulting in further loss of lives. Lockdowns disproportionately affect the poor and widen the already existing inequities within these societies. Mitigating the pandemic must of necessity include the provision of adequate healthcare services to treat all people with COVID-19, which remains a challenge within Africa's fragile health systems. Inadequate supply of oxygen was a prepandemic challenge in many parts of Africa, which has been exacerbated by the pandemic as increased demand for oxygen far outstripped supply. Although some efforts have been made to mitigate the deficits in oxygen supply with some African countries, such as Nigeria and Malawi having made some strides in improving oxygen supply by establishing new infrastructure for production and delivery, these efforts have not been enough. One major health need in the COVID-19 pandemic is the availability of critical care services including care and treatment of respiratory failure using supportive ventilation. Across sSA, the availability of critical care beds and associated resources for the provision of care and treatment of critically ill patients with COVID-19 is dismal. This calls for the mobilization of resources not only for infrastructural development but also for capacity building. Trained healthcare workers in this area are limited, and task shifting for critical care has proven feasible in Africa and requires further consideration (33). Vaccination, which is considered one of the most cost-effective strategies for mitigating and containing this pandemic, has underscored the global inequities that exist today. While countries such as Canada, United Kingdom, and Israel have achieved nearly 70% vaccination rates, Africa is yet to reach the 3% mark targeted by the World Health Organization (WHO) under the COVID-19 Vaccines Global Access (COVAX) facility as of mid-July 2021. Indeed, most African countries have vaccinated <1% of the population with one dose of the vaccine. The decisive and proactive measures taken by the African Center for Disease Control to mitigate this pandemic, which included the Partnership to Accelerate COVID-19 Testing (PACT) and more recently procurement and equitable distribution of donated vaccines through the COVAX facility, are The early development of a African strategy by African in the early of this pandemic may have contributed to the low numbers of COVID-19 cases and related deaths in Africa. However, more needs to be with to vaccine access and effective in Africa. COVAX will million of the which can only a third of the African population, that countries need to vaccines to and will remain key challenges for the African setting, and there is a need for the global to strategies to scale up vaccine coverage for African In addition, vaccine in the African setting will need to be with to ensure vaccines made through the are taken up by the population in a vaccine in of Africa where key behavior of is an important mitigation strategy that requires public health The spread of through the wide of social in Africa must be by that is in to vaccine when vaccines become more As countries to from this pandemic due to in the high rates of Africa must not be left The spread of SARS-CoV-2 from to a global pandemic as a and that global health is of or are by the and and and and final version of B. PDF to World (COVID-19) TB. COVID-19 the African Health An of asthma prevalence in Africa: a of An of the prevalence of COPD in Africa: a COPD The of chronic obstructive pulmonary disease in low countries of Africa. of Global for the and prevention of chronic obstructive lung disease. The 2020 on COVID-19 and Chronic 2021. of with access to spirometry in Africa: a on challenges and Health of factors for severity and mortality in patients infected with a One and outcomes of COVID-19 in HIV-infected a and 2021. of hypertension and adults in a analysis on of obesity and an of the between and in urban Lagos, 2021. and national of pneumonia morbidity and mortality in children than 5 years between and a Health of and national mortality for causes of death in countries and a analysis for the Global of Disease of The global burden of respiratory on child health. of function in African in the Child Health of lower respiratory tract illness. of of of asthma, and in to children in Africa: the of Asthma and in Childhood of Asthma and management among in urban from a challenges to out COVID-19

The Effect of COVID-19 on Radiation Oncology Professionals and Patients With Cancer: From Trauma to Psychological Growth

As the COVID-19 pandemic accelerates in the United States, this commentary asks how oncology specialists and allied providers are balancing a delay in cancer diagnosis or treatment against the risk...

Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy